Auswahl der wissenschaftlichen Literatur zum Thema „AMQ 7“

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "AMQ 7" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "AMQ 7"

1

Engelhardt, LM, PC Healy, JD Kildea, BW Skelton und AH White. „Lewis-Base Adducts of Group 11 Metal(I) Compounds. LV. Synthesis and Structures of 1 : 1 Copper(I) Halide (Cl, Br, I)/2-Aminoquinoline Complexes“. Australian Journal of Chemistry 42, Nr. 6 (1989): 933. http://dx.doi.org/10.1071/ch9890933.

Der volle Inhalt der Quelle
Annotation:
1 : 1 Adducts of the copper(I) halides, CuX (X=CI, Br, I), with 2-aminoquinoline (amq) have been synthesized by the crystallization of stoichiometric mixtures of these components from acetonitrile solution, and their structures determined by single-crystal X-ray methods; they are found to span a diverse array of structural types. The chloride crystallizes as a 'stair polymer' array [monoclinic, P21, a 7.487(6), b 3.771(7), c 15.506(2) � , 95.07(4)�, Z= 2]. The bromide is a centrosymmetric dimer , solvated by acetonitrile, [( amq )( MeCN )CuBr2Cu( MeCN )( amq )] [triclinic, PI, a 17.325(8), b 10.376(3), c 7.204(9) �, α 70.36(6), β 88.13(7), γ 77.52(3) �, Z= 2 dimers]; Cu-Br range from 2.551(2)-2.668(2); Cu-N( amq ) are 2.021(8), 2.010(6); Cu-N( MeCN ) are 1.986(8), 1.960(7) A (two independent dimers ). The iodide alone forms the expected single-strand 'split-stair' polymer [monoclinic, P21, a 12.090(5), b 9.971(5), c 4.132(2) � , P 98. 50(3) �, Z = 21, Cu-I, 2.527(3), 2. 567(3); Cu-N, 2.02(2) � . Residuals were 0.035, 0.050, 0.045 for 552, 2974, 608 independent 'observed' reflections respectively.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Mautner, Franz A., Roland C. Fischer, Ana Torvisco, Nahed M. H. Salem, Amber R. Dugas, Shelby F. Aaron, Sushant P. Sahu, Febee R. Louka und Salah S. Massoud. „Stereochemical Geometries and Photoluminescence in Pseudo-Halido-Zinc(II) Complexes. Structural Comparison between the Corresponding Cadmium(II) Analogs“. Inorganics 9, Nr. 7 (09.07.2021): 53. http://dx.doi.org/10.3390/inorganics9070053.

Der volle Inhalt der Quelle
Annotation:
Six pseudohalide zinc(II) containing a variety of N-donor auxiliary amines were structurally characterized. These include two mononuclear trigonal bipyramidal [Zn(NTB)(N3)]ClO4·½H2O (3) and [Zn(TPA)(NCS)]ClO4 (4), two distorted octahedral [Zn(1,8-damnph)2(dca)2] (5) and [Zn(8-amq)2(dca)2] (6a) as well as two 1D polymeric chains catena-[Zn(isq)2(μ1,5-dca)2] (7) and catena-[Zn(N,N-Me2en)2(μ1,5-dca)]dca (8), where NTB = tris(2-benzimidazolylmethyl)amine, TPA = tris(2-pyridylmethyl)amine, 1,8-damnph = 1,8-diaminonaphthalene, 8-amq = 8-amino-quinoline, isq = isoquinoline (isq) and N,N-Me2en = N,N-dimethylethylenediamine. In general, with the exception of 6 and 8, the complexes exhibited luminescence emission in MeOH associated with red shift of the emission maxima, and the strongest visible fluorescence peak was detected at 421 nm (λex = 330 nm) in the case of Complex 5.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Maertens, Johan A., Hedy Teppler, Robert Lupinacci, Michael Bourque, Mark DiNubile und Carole Sable. „Empirical Antifungal Therapy (Rx) with Caspofungin (CAS) vs Liposomal Amphotericin B (L-AmB) for Persistently Febrile Neutropenic Patients (Pts) with Acute Myeloid Leukemia (AML).“ Blood 104, Nr. 11 (16.11.2004): 1337. http://dx.doi.org/10.1182/blood.v104.11.1337.1337.

Der volle Inhalt der Quelle
Annotation:
Abstract Background: In a double-blind randomized trial of empirical antifungal Rx for persistently febrile neutropenic pts, CAS was as effective as and better tolerated than L-AmB. We now examine the results of this study in the subgroup of pts with AML. Methods: Randomization to CAS (70 mg x 1, then 50 mg/d) or L-AmB (3 mg/kg/d) was stratified by risk category [high risk = allogeneic hematopoietic stem cell transplant or relapsed acute leukemia] and use of antifungal prophylaxis. The primary efficacy endpoint was % of treated pts with documented fever and neutropenia who had a successful outcome defined by all the following: successful Rx of baseline (BL) invasive fungal infection (IFI) (if any), no breakthrough (BT) IFI to 7 d post-Rx, survival @7d post-Rx, no premature discontinuation (DC) due to lack of efficacy or study drug toxicity, and fever resolution x 48 hr during neutropenia. Results: 703/1095 (64%) of the treated pts had AML, including 364/556 (65%) and 339/539 (63%) in the CAS and L-AmB groups, respectively. Demographic characteristics were similar in AML pts in both Rx groups. 27% of CAS and 22% of L-AmB pts with AML were high risk. Median days of Rx were: CAS, 12; L-AmB, 11. The table shows % AML pts with a successful outcome by Rx group. % AML pts with a successful outcome by Rx group CAS (N=364) L-AmB (N=339) Difference (CAS - L-AmB) 95% CI for difference between treatment groups † 7/14 CAS and 5/16 L-AmB pts had successful Rx of BL IFI. Success Rx of BL IFI † 50 31 19 (−16, 53) No BT IFI 93 95 −2 (−5, 2) Suvival @ 7d post-Rx 92 88 4 (0, 8) No premature DC 87 86 2 (−3, 7) Fever resolution 48 46 2 (−5, 9) All of the above 40 38 2 (−5, 10) The composite success rates for the high risk AML pts were 46/99 (46%) for CAS and 31/76 (41%) for L-AmB. Conclusions: In this post hoc subgroup analysis, CAS provided an effective and generally well-tolerated option for the empirical Rx of persistently febrile neutropenic pts with AML.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Erba, Harry Paul, Pamela S. Becker, Paul J. Shami, Michael Richard Grunwald, Donna L. Flesher, Yilong Zhang, Erik Rasmussen, Haby A. Henary und Eunice S. Wang. „Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML).“ Journal of Clinical Oncology 35, Nr. 15_suppl (20.05.2017): 7027. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.7027.

Der volle Inhalt der Quelle
Annotation:
7027 Background: The ubiquitin ligase MDM2 inhibits the tumor suppressor p53. In preclinical AML models, MDM2 inhibitors have antitumor activity as monotherapy that is synergistic when combined with MEK inhibitors. This open-label phase 1b study assessed the maximum tolerated dose (MTD), pharmacokinetics (PK), and preliminary antitumor activity of the investigational oral, selective MDM2 inhibitor AMG 232 as monotherapy or combined with the MEK kinase inhibitor trametinib in pts with r/r AML. Methods: Pts with r/r AML received AMG 232 for 7 days every 2 weeks (7 days on/7 days off) at 60, 120, 240, 480, and 960 mg PO QD as monotherapy (Arm 1) or combined with trametinib 2 mg PO QD (Arm 2). Primary endpoints were the incidence of adverse events (AEs), dose-limiting toxicities (DLTs), and PK. Additional endpoints included best response (revised IWG) and serum MIC-1 level (increased MIC-1 suggests p53 activation). p53 target gene ( P21, BAX, and PUMA) expression in bone marrow was assessed by microarray. Results: In total, 35 pts (Arm 1, n = 26; Arm 2, n = 9; median age, 68 y; range, 26–86) were treated. Arm 1 enrolled AMG 232 at 60 mg (n = 4), 90 mg (n = 4), 180 mg (n = 5), 240 mg (n = 3), and 360 (n = 10). Twenty-two (85%) pts in Arm 1 had treatment-related AEs; the most common were nausea (n = 14), diarrhea (n = 14), and vomiting (n = 6). No DLTs occurred; one pt is still on treatment. The MTD was determined as 360 mg based on tolerance of gastrointestinal toxicity. Arm 2 enrollment is ongoing at a fixed AMG 232 dose of 60 mg plus trametinib (n = 9). AMG 232 plasma exposure increased with dose escalation; PK was unaffected by trametinib. Trametinib PK was as expected. Increases from baseline (BL) to day 10 in serum MIC-1 were dose dependent. Evidence of increased P21, BAX, and PUMA expression (BL to day 7 or 8) was seen (n = 3). One pt (Arm 2) had complete remission (CR); three pts (Arm 1) achieved CRi/MLFS. Median response duration was 66 days [range, 21–377+]). Conclusions: AMG 232 monotherapy was tolerable in pts with r/r AML at doses up to 360 mg on a 7 days on/7 days off schedule with expected PK, on-target biological effects, and early evidence of antileukemia activity. Clinical trial information: NCT02016729.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Pevnick, Joshua M., Caroline Nguyen, Cynthia A. Jackevicius, Katherine A. Palmer, Rita Shane, Galen Cook-Wiens, Andre Rogatko et al. „Improving admission medication reconciliation with pharmacists or pharmacy technicians in the emergency department: a randomised controlled trial“. BMJ Quality & Safety 27, Nr. 7 (06.10.2017): 512–20. http://dx.doi.org/10.1136/bmjqs-2017-006761.

Der volle Inhalt der Quelle
Annotation:
BackgroundAdmission medication history (AMH) errors frequently cause medication order errors and patient harm.ObjectiveTo quantify AMH error reduction achieved when pharmacy staff obtain AMHs before admission medication orders (AMO) are placed.MethodsThis was a three-arm randomised controlled trial of 306 inpatients. In one intervention arm, pharmacists, and in the second intervention arm, pharmacy technicians, obtained initial AMHs prior to admission. They obtained and reconciled medication information from multiple sources. All arms, including the control arm, received usual AMH care, which included variation in several common processes. The primary outcome was severity-weighted mean AMH error score. To detect AMH errors, all patients received reference standard AMHs, which were compared with intervention and control group AMHs. AMH errors and resultant AMO errors were independently identified and rated by ≥2 investigators as significant, serious or life threatening. Each error was assigned 1, 4 or 9 points, respectively, to calculate severity-weighted AMH and AMO error scores for each patient.ResultsPatient characteristics were similar across arms (mean±SD age 72±16 years, number of medications 15±7). Analysis was limited to 278 patients (91%) with reference standard AMHs. Mean±SD AMH errors per patient in the usual care, pharmacist and technician arms were 8.0±5.6, 1.4±1.9 and 1.5±2.1, respectively (p<0.0001). Mean±SD severity-weighted AMH error scores were 23.0±16.1, 4.1±6.8 and 4.1±7.0 per patient, respectively (p<0.0001). These AMH errors led to a mean±SD of 3.2±2.9, 0.6±1.1 and 0.6±1.1 AMO errors per patient, and mean severity-weighted AMO error scores of 6.9±7.2, 1.5±2.9 and 1.2±2.5 per patient, respectively (both p<0.0001).ConclusionsPharmacists and technicians reduced AMH errors and resultant AMO errors by over 80%. Future research should examine other sites and patient-centred outcomes.Trial registration numberNCT02026453.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Cheung, Kam, Gloria Juan, William Wayne, Kelly Hanestad, Kathleen Keegan, Justin Huard, Patricia McElroy et al. „AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo“. Blood 122, Nr. 21 (15.11.2013): 3823. http://dx.doi.org/10.1182/blood.v122.21.3823.3823.

Der volle Inhalt der Quelle
Annotation:
Abstract Aurora kinases A and B play essential roles in multiple stages of mitosis and are frequently overexpressed in a subset of human cancers, including acute myeloid leukemia (AML) (Ikezoe T et al, 2007). AMG 900, a potent and highly selective small molecule inhibitor of aurora kinases, is currently in Phase 1 clinical testing in adult patients with AML. In this study, we report the preclinical effects of AMG 900 in AML cell lines. We show that AMG 900 inhibits the phosphorylation of Histone H3 on serine-10 (a proximal substrate of aurora-B) leading to aborted cell division, apoptosis and/or polyploidy. We evaluated the activity of AMG 900 and two other well-characterized aurora kinase inhibitors [AZD1152-hQPA (B-selective AKI) and MLN8054 (A-selective AKI)] in a panel of AML cell lines. AMG 900 inhibited proliferation in all 10 cell lines at single-digit nanomolar concentrations. At effective concentrations, AMG 900 and AZD1152-hQPA showed similar cellular phenotypes, indicating that the activity of AMG 900 may occur through inhibition of aurora-B. A subset of cell lines sensitive to AMG 900 and MLN8054 were insensitive to AZD1152-hQPA, suggesting that AMG 900 may be less susceptible to resistance mediated by drug-efflux (Grundy M et al, 2011). Two AMG 900 oral dosing schedules are being evaluated in the ongoing AML clinical trial; patients receive either 4 or 7 consecutive daily doses followed by a drug holiday in 14-day cycles. In this study, we evaluated the in vivo anti-proliferative effects of AMG 900 using the two dose schedules in the skeleton of NOD/SCID IL2γnull mice bearing MOLM-13 (AML) cells expressing luciferase. To assess tumor cell proliferation in vivo, we used 18FLT (radioactive thymidine analog) PET/CT imaging, a technique that has been used to monitor early treatment response in the bone marrow of AML patients (Vanderhoek M et al, 2011). Mice were imaged for luciferase activity and 18FLT uptake before treatment and at multiple time-points during the drug holiday phase within the 14-day cycle. While the two AMG 900 dosing schedules resulted in a similar decrease in tumor burden across study time points (as measured by luciferase activity), they differed in the timing of skeletal 18FLT responses. Mice administered AMG 900 showed an attenuated skeletal 18FLT uptake compared with the vehicle group, followed by an 18FLT flare. This 18FLT flare event is notably higher using the AMG 900 4-day schedule, although the cumulative dose is similar for both schedules. This difference in 18FLT flaring may indicate the schedules differ in the duration and/or level of target inhibition in the skeletal tumor and bone marrow cells. Mice treated with sunitinib (positive control agent) did not show a skeletal 18FLT flare during the drug holiday, suggesting its mode of action is distinct from that of AMG 900. At the end of the study, mouse bone marrow was assessed for tumor burden by flow cytometry. Mice treated with AMG 900 showed a significant decrease in tumor burden compared with the vehicle group. Interestingly, the mice administered AMG 900 7-day schedule showed the most suppression of tumor growth compared with either AMG 900 4-day schedule or sunitinib. Together, our preclinical studies demonstrate that AMG 900 is a potent inhibitor of aurora kinases that robustly suppresses the growth of AML cells in vitro and in vivo. Furthermore, we highlight the utility of in vivo imaging to monitor AMG 900 drug action, which may help to inform future dose scheduling and drug combination studies. Disclosures: Cheung: Amgen Inc: Employment, Equity Ownership. Juan:Amgen Inc.: Employment, Equity Ownership. Wayne:Amgen Inc.: Employment, Equity Ownership. Hanestad:Amgen Inc.: Employment, Equity Ownership. Keegan:Amgen Inc.: Employment, Equity Ownership. Huard:Amgen Inc.: Employment, Equity Ownership. McElroy:Amgen Inc.: Employment, Equity Ownership. Stanton:Amgen Inc.: Employment, Equity Ownership. Bush:Amgen Inc.: Employment, Equity Ownership. Kendall:Amgen Inc.: Employment, Equity Ownership. Radinsky:Amgen Inc.: Employment, Equity Ownership. Abella:Amgen Inc. : Employment, Equity Ownership. Pieslor:Amgen Inc.: Employment, Equity Ownership. Friberg:Amgen Inc.: Employment, Equity Ownership. Coxon:Amgen Inc.: Employment, Equity Ownership. Gamelin:Amgen Inc: Employment, Equity Ownership. Payton:Amgen Inc.: Employment, Equity Ownership. Off Label Use: AMG 900 is currently in phase 1 clinical development, there is no approved label.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Gemelli, E., S. Lourenci, M. V. Folgueras und N. H. Almeida Camargo. „Assessment of industrial wastes in mortar layers deposited on stainless steel sheets of sinks“. Cerâmica 50, Nr. 316 (Dezember 2004): 336–44. http://dx.doi.org/10.1590/s0366-69132004000400009.

Der volle Inhalt der Quelle
Annotation:
This work deals with the properties of alternative mortars destined to strengthen metal sheets of sinks. The performance of these mortars was compared to that of a basic mortar made of cement, sand, and water, named standard mortar (SM). One of these mortars, named alternative mortar 2 (AM2), and composed of cement, textile residue, polyurethane, polypropylene fibers and water, was developed recently to replace the current one, named alternative mortar 1 (AM1), composed of cement, sand, polystyrene, polypropylene fibers and water. These mortars were manufactured and aged in a room in atmospheric environment for 7, 14, 28, 60 and 90 days, either with or without initial drying in a furnace. After cure of 90 days the flexion strength stress of the SM, AM1 and AM2 mortars was 5.21, 3.84, and 1.42 MPa, respectively. The SM and AM1 mortars were constituted of C-S-H phases, Ca(OH)2, SiO2, AFm and AFt (monossulphate/ettringite) phases. The AM2 mortar presented, apart from the compounds mentioned above, CaCO3. This compound is from the textile residue that is composed essentially of CaCO3 and Ca(OH)2. The reduction in flexion strength of AM1 mortar, compared to SM mortar, is caused by the polystyrene whereas the lowering mechanical strength of the AM2 is due to both polyurethane and textile residue. Even so, its mechanical strength is acceptable because the flexion strength stress required for the industrial application is 1.0 MPa.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Longo, Flavio Alves, José Fernando Machado Menten, Adriana Ayres Pedroso, Adriana Nogueira Figueiredo, Aline M. Calil Racanicci, Juliano Benedito Gaiotto und José Otávio Berti Sorbara. „Carboidratos na dieta pré-inicial de frangos de corte“. Revista Brasileira de Zootecnia 34, Nr. 1 (Februar 2005): 123–33. http://dx.doi.org/10.1590/s1516-35982005000100016.

Der volle Inhalt der Quelle
Annotation:
Objetivou-se, com este estudo, determinar a energia metabolizável aparente corrigida (EMAn) de ingredientes como fonte de carboidrato para frangos de corte de 1 a 7 dias de idade, bem como avaliar a utilização destes diferentes ingredientes em dietas pré-iniciais sobre o desenvolvimento inicial de órgãos do trato gastrintestinal (TGI) e desempenho das aves. No Experimento 1, foi utilizado o método de coleta total das excretas com 220 pintos de 4 a 7 dias de idade, alojados em baterias em delineamento inteiramente casualizado com cinco tratamentos (uma dieta-referência e quatro dietas com inclusão de 20% do ingrediente-teste - amido de milho [AMI], amido de mandioca [AMA], glicose [GLI] e sacarose [SAC]) e quatro repetições de 11 aves. No Experimento 2, foram utilizados 520 pintos de corte machos de um dia de idade, distribuídos em delineamento inteiramente casualizado, com cinco tratamentos e quatro repetições de 26 aves. Os tratamentos foram aplicados de 1 a 7 dias e, no período subseqüente, as aves tiveram acesso a uma dieta basal padrão. Os tratamentos consistiram em: 1 - dieta de milho e farelo de soja, 2 - dieta de milho e farelo de soja + AMI, 3 - dieta de milho e farelo de soja + AMA, 4 - dieta de milho e farelo de soja + GLI, 5 - dieta de milho e farelo de soja + SAC. O valor da EMAn determinado para frangos de corte na fase pré-inicial foi de 3.269, 3.690, 3.427 e 3.524 kcal/kg para AMI, AMA, GLI e SAC, respectivamente. Observou-se que o desenvolvimento do TGI, de maneira geral, não foi influenciado pelos diferentes tratamentos, mas o consumo de ração das aves foi aumentado com o fornecimento de carboidrato de maior disponibilidade na dieta pré-inicial, contribuindo para aumento no peso vivo das aves.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Erba, Harry P., Pamela S. Becker, Paul J. Shami, Michael R. Grunwald, Donna L. Flesher, Min Zhu, Erik Rasmussen, Haby A. Henary, Abraham A. Anderson und Eunice S. Wang. „Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia“. Blood Advances 3, Nr. 13 (28.06.2019): 1939–49. http://dx.doi.org/10.1182/bloodadvances.2019030916.

Der volle Inhalt der Quelle
Annotation:
AbstractThis open-label, phase 1 study evaluated the safety, pharmacokinetics, and maximum tolerated dose of AMG 232, an investigational oral, selective mouse double minute 2 homolog inhibitor in relapsed/refractory acute myeloid leukemia (AML). AMG 232 was administered orally once daily for 7 days every 2 weeks (7 on/off) at 60, 120, 240, 360, 480, or 960 mg as monotherapy (arm 1) or at 60 mg with trametinib 2 mg (arm 2). Dose-limiting toxicities (DLTs), adverse events (AEs), pharmacokinetics, clinical and pharmacodynamic response, and expression of p53 target genes were assessed. All 36 patients received AMG 232. No DLTs occurred in arm 1, and 360 mg was the highest test dose; dose escalation was halted due to gastrointestinal AEs at higher doses. One of ten patients in arm 2 had a DLT (grade 3 fatigue); 60 mg was the highest dose tested with trametinib. Common treatment-related AEs (any grade) included nausea (58%), diarrhea (56%), vomiting (33%), and decreased appetite (25%). AMG 232 exhibited linear pharmacokinetics unaffected by coadministration with trametinib. Serum macrophage inhibitor cytokine-1 and bone marrow expression of BAX, PUMA, P21, and MDM2 increased during treatment. Of 30 evaluable patients, 1 achieved complete remission, 4 had morphologic leukemia-free state, and 1 had partial remission. Four of 13 (31%) TP53-wild-type patients and 0 of 3 (0%) TP53-mutant patients were responders. AMG 232 was associated with gastrointestinal AEs at higher doses but had acceptable pharmacokinetics, on-target effects, and promising clinical activity warranting further investigation in patients with relapsed/refractory AML. This trial was registered at www.clinicaltrials.gov as #NCT02016729.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Jehn, U., R. Zittoun und B. Löwenberg. „AML-6- und AML-7-Studie zur Behandlung der akuten myeloischen Leukämie“. Oncology Research and Treatment 8, Nr. 3 (1985): 160–64. http://dx.doi.org/10.1159/000215646.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Dissertationen zum Thema "AMQ 7"

1

Dubaj, Ondrej. „Systém pro správu výsledků testů doplňující nástroj tmt“. Master's thesis, Vysoké učení technické v Brně. Fakulta informačních technologií, 2021. http://www.nusl.cz/ntk/nusl-445546.

Der volle Inhalt der Quelle
Annotation:
This diploma thesis deals with the area of software testing, more precisely with the topic of managing test results. The aim of this work is to find, set up and implement a system that complements the missing functionality of the TMT tool, which is going to replace the Nitrate tool in Red Hat as a test management system. The content of this work is a basic introduction to the tools Nitrate, TMT and other technologies used in Red Hat. Furthermore, the work presents the current state of the test infrastructure and collected user requirements for a new system for managing test results. Subsequently, the ReportPortal tool is introduced as a system for test results management and the missing functionality is defined. The rest of the work is devoted to setting up the system itself and implementing the missing functionality, along with implementing the infrastructure needed to import test results into ReportPortal. The work describes the method of deploying the system in use and feedback from users. The deployed system is evaluated and its further possible improvements are discussed.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Ludwig, Ulrike. „Militärrecht in der Frühen Neuzeit. 7. Tagung des AMG (Bayreuth, 4.-7. Oktober 2007)“. Universität Potsdam, 2007. http://opus.kobv.de/ubp/volltexte/2008/2125/.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Fiedler, Hannah [Verfasser]. „RUNX1-Mutationen bei AML-Patienten mit Monosomie 7 / Anderen Chromosom 7 Veränderungen / Hannah Fiedler“. Ulm : Universität Ulm. Medizinische Fakultät, 2016. http://d-nb.info/1093557648/34.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Senate, University of Arizona Faculty. „Faculty Senate Minutes May 7, 2012“. University of Arizona Faculty Senate (Tucson, AZ), 2012. http://hdl.handle.net/10150/244391.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Bel, Oleart Tomàs. „Anàlisi de la respost a cognitiva i afectiva en la interacció amb una instal·lació d'art“. Doctoral thesis, Universitat Autònoma de Barcelona, 2014. http://hdl.handle.net/10803/133228.

Der volle Inhalt der Quelle
Annotation:
El model de Helmud Leder defineix i ordena els processos afectius i cognitius que es troben implicats en l´experiència estètica. Basant-nos en aquest model hem estudiat la resposta estètica d´una mostra de noies estudiants de disseny a qui s´ha proposat d´interaccionar amb una instal·lació d´art. Les participants cumplimentaven diversos qüestionaris pre-post mitjançant els quals es registraven aspectes de la valència afectiva, l´autoconsciència i l´ansietat. Posteriorment a l´experiència en la instal·lació es passaven altres qüestionaris per recollir els judicis sobre la qualitat de l´experiència i sobre la interpretació dels elements significants de la instal·lació, així com del grau de coherència de cadascun d´aquests elements amb el conjunt. Mitjançant la comparació de les dades obtingudes de totes les participants abans i després de l´experiència en la instal·lació, hem analitzat fins a quin punt es donaven tendències detectables en els canvis cognitius i afectius que poguessin ser depenents del material estimular. Per altra banda i per tal de contrastar la influència d´aportació prèvia d´informació sobre els continguts conceptuals de la instal·lació en la resposta de les participants vam definir dos sub-grups, un dels quals rebia informació suplementària sobre els continguts de la instal·lació, mentre que l´altre no en rebia. Els resultats obtinguts suggereixen que la instal·lació d´art “H1” té la propietat de generar canvis en algunes de les variables afectives i cognitives estudiades, i que l´aportació d´informació bàsica addicional sobre els conceptes representats en aquesta instal·lació afecta a determinats aspectes de la resposta de les participants, tant afectius com cognitius.
Helmud Leder’s model defines and orders the affective and cognitive processes involved in the aesthetic experience. On the basis of this model, we studied the aesthetic response of a sample of female design students, who were invited to interact with an art installation. The participants filled in various pre-post questionnaires to record aspects of affective valence, self-consciousness and anxiety. After the experience in the installation, they were given other questionnaires to find out their opinions on the quality of the experience and their interpretation of the significant elements of the installation, and the degree of consistency of each of these elements with the installation as a whole. By comparing the data obtained from all the participants before and after the experience in the installation, we analysed the extent to which there were detectable trends in cognitive and affective changes that may be dependent on the stimulating material. Meanwhile, in order to verify the influence of previously provided information on the conceptual content of the installation in the response of participants, we defined two sub-groups, one of which received additional information on the contents of the installation, while the other did not. The results suggest that the “H1” art installation has the property of generating changes in some of the affective and cognitive variables studied, and that the provision of additional basic information on the concepts represented in the installation affects certain aspects of both the cognitive and affective response of the participants.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Tew, Marilyn Wilson. „The lifeworld of Year 7 pupils : personal development and learning“. Thesis, University of Bristol, 2003. http://hdl.handle.net/1983/9c1153f4-7c25-4816-9f4e-ab2d3cc163ac.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Vardar, Emine. „Sixth, Seventh And Eighth Grade Teachers&#039“. Master's thesis, METU, 2010. http://etd.lib.metu.edu.tr/upload/12612141/index.pdf.

Der volle Inhalt der Quelle
Annotation:
The main purpose of this study was to investigate sixth, seventh, and eight gradeTurkish, English, Mathematics, Science and Technology, and Social Studies teachers&rsquo
conceptions of assessment. It was also aimed at finding out the differences, if any, in teachers&rsquo
conceptions of assessment according to their teaching subject, years of teaching experience, in-service training, and the undergraduate institution they graduated from. There were 414 teachers included in the study. Data were gathered through the short version of Teacher Conceptions of Assessment Scale (TCoA-IIIA), which had 27 items. Exploratory Factor Analysis results revealed that there were four factors in the scale which were called Student Accountability, School Accountability, Improvement, and Irrelevance like in the original scale. Then, the correlation results revealed that Student Accountability, School Accountability and Improvement conceptions were significantly correlated with each other at moderate level. However, Irrelevance conception did not have a significant relationship with other conceptions. The findings of Multivariate Analysis of Variance (MANOVA) indicated that teaching subject and in-service training did not make any significant difference in teachers&rsquo
conceptions of assessment. However, years of teaching experience and undergraduate institution teachers graduated did significant differences in teachers&rsquo
conceptions of assessment.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Burchartz, Birgit. „Problemlöseverhalten von Schülern beim Bearbeiten unlösbarer Probleme /“. Hildesheim [u.a.] : Franzbecker, 2003. http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&doc_number=010263298&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Crutchfield, Gerald L. „Kruppel-Like Transcription Factor 6 & 7 mRNAs (KLF6 & KLF7) Expression in the Developing Zebrafish“. University of Akron / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=akron1572200378181869.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Kruse, Jessica, und Kristina Isik. „Implementeringen av IFRS 7 i svenska livförsäkringsbolag“. Thesis, Södertörn University College, School of Business Studies, 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:sh:diva-662.

Der volle Inhalt der Quelle
Annotation:

Concurrently with higher demands on comparability between companies, all Swedish listed parent companies are guilty to apply international accounting standards, IFRS/IAS, no later than January 1, 2005. In this thesis IFRS 7 Financial instruments: Disclosures, that treats information about financial instruments, is investigated. IFRS 7 aims to establish a good international standard for disclosures about financial instruments. The purpose of this thesis is to study differences in the interpretation of IFRS 7 Financial instruments: Disclosures between Swedish life insurance companies, problems – if any – that associate with the recommendation, the recommendation’s effect on accounting and the attitudes towards IFRS amongst the Swedish life insurance companies. The thesis is based on a qualitative method and the conclusion of the thesis is that the life insurance companies find it tricky to decide how the accounting shall be designed in compliance with IFRS 7. Almost all information needed already exists. The problem rather relates to the design of the accounting. Further more, the companies read the recommendation with different eyes and define different users of annual reports, that creates different interpretations. Balance- and income statements will be less affected of IFRS 7, while notes and disclosures will grow. Finally, the attitudes towards IFRS vary alot between life insurance companies.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Bücher zum Thema "AMQ 7"

1

Niezrecki, Christopher, Hrsg. Structural Health Monitoring & Damage Detection, Volume 7. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-54109-9.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Di Maio, Dario, Hrsg. Rotating Machinery, Vibro-Acoustics & Laser Vibrometry, Volume 7. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-74693-7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Wicks, Alfred, und Christopher Niezrecki, Hrsg. Structural Health Monitoring, Damage Detection & Mechatronics, Volume 7. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-29956-3.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Eska, Georg. Schall & Klang. Basel: Birkhäuser Basel, 1997. http://dx.doi.org/10.1007/978-3-0348-6100-7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Olteanu, Alin, Andrew Stables und Dumitru Borţun, Hrsg. Meanings & Co. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-91986-7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Jansen, Stephan A. Mergers & Acquisitions. Wiesbaden: Springer Fachmedien Wiesbaden, 2016. http://dx.doi.org/10.1007/978-3-8349-4772-7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Hyde, Richard M. Microbiology & Immunology. New York, NY: Springer New York, 1995. http://dx.doi.org/10.1007/978-1-4613-8439-7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

McConachie, Bruce. Theatre & Mind. London: Macmillan Education UK, 2013. http://dx.doi.org/10.1007/978-1-137-01561-7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Davis, Jim. Theatre & Entertainment. London: Macmillan Education UK, 2016. http://dx.doi.org/10.1007/978-1-137-32107-7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Ridout, Nicholas. Theatre & Ethics. London: Macmillan Education UK, 2009. http://dx.doi.org/10.1007/978-0-230-36454-7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Buchteile zum Thema "AMQ 7"

1

Sumerau, J. E. „Chapter 7“. In Cigarettes & Wine, 37–44. Rotterdam: SensePublishers, 2017. http://dx.doi.org/10.1007/978-94-6300-929-4_7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Owens, Justin M., Michael Clamann, David Aylor, Stacy A. Balk, Jana Lynott, Maya Pindeus, Amy Rosepiler, Lauren Silverstein und Francis Gemperle. „Automated Vehicles & Vulnerable Road Users: Representing the Under-Represented“. In Road Vehicle Automation 7, 97–107. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-52840-9_10.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Kao, Robert, Dante Sarigumba, Anthony Rizk und Kevin Michaluk. „Where Am I? Using Location-Based Services“. In Beginning BlackBerry 7 Development, 201–23. Berkeley, CA: Apress, 2011. http://dx.doi.org/10.1007/978-1-4302-3016-8_8.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Bornstein, George, und Warwick Gould. „“To a Sister of the Cross & the Rose”: An Unpublished Early Poem“. In Yeats Annual No. 7, 179–83. London: Palgrave Macmillan UK, 1990. http://dx.doi.org/10.1007/978-1-349-07951-3_11.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

„.. ( #!' #) &+ 7&)) "8% #)(“. In Reproductive Biology and Phylogeny of Birds, Part A, 214–27. CRC Press, 2011. http://dx.doi.org/10.1201/b10750-11.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

„!"#$7 '.-,"#' '-& &( &-!# '#!-,"#&+$'%88/“. In Views of Ancient Egypt since Napoleon Bonaparte, 103–10. Routledge, 2016. http://dx.doi.org/10.4324/9781315416014-4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

„Comments on Lahiri & Reetz“. In Laboratory Phonology 7, 677–86. De Gruyter Mouton, 2002. http://dx.doi.org/10.1515/9783110197105.2.677.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

„7 & 8“. In Small Animal Emergency & Critical Care Medicine, 9–10. CRC Press, 1999. http://dx.doi.org/10.1201/b15212-4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

„!"#$8 -,"#(#!(&)&'') #)$“. In Views of Ancient Egypt since Napoleon Bonaparte, 143–62. Routledge, 2016. http://dx.doi.org/10.4324/9781315416014-7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

„7. Auswahlbibliographie“. In Rock & Religion, 259–70. transcript-Verlag, 2012. http://dx.doi.org/10.14361/transcript.9783839420508.259.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "AMQ 7"

1

„7. Fields, Waves & Electromagnetics“. In 2020 IEEE Conference of Russian Young Researchers in Electrical and Electronic Engineering (EIConRus). IEEE, 2020. http://dx.doi.org/10.1109/eiconrus49466.2020.9039254.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

„Session 7: Queue & Buffer Management“. In Proceedings. 13th International Conference on Computer Communications and Networks. IEEE, 2004. http://dx.doi.org/10.1109/icccn.2004.1401605.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Gyselinckx, Bert, Hiroshi Kanayama, Michael McCool, Shintaro Momose, Takeshi Kataoka, James Myers und Toshio Yoshida. „Keynote & invited speaker's biography [7 biographies]“. In 2013 COOL Chips XVI. IEEE, 2013. http://dx.doi.org/10.1109/coolchips.2013.6547912.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

„Keynote addresses & special symposiums [7 abstracts]“. In 2014 IEEE 3rd Global Conference on Consumer Electronics (GCCE). IEEE, 2014. http://dx.doi.org/10.1109/gcce.2014.7031082.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

„Track 7: Spacecraft Avionics Systems & Technologies“. In 2007 IEEE Aerospace Conference. IEEE, 2007. http://dx.doi.org/10.1109/aero.2007.352632.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

„Session 7 Device characteristics, modeling & simulation“. In 2004 IEEE International SOI Conference. IEEE, 2004. http://dx.doi.org/10.1109/soi.2004.1391592.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Symons, R., und R. Woods. „Session 7 Electron tubes&#8212;General“. In 1987 International Electron Devices Meeting. IRE, 1987. http://dx.doi.org/10.1109/iedm.1987.191370.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Standaert, T., G. Beique, H. C. Chen, S. T. Chen, B. Hamieh, J. Lee, P. McLaughlin et al. „BEOL process integration for the 7 nm technology node“. In 2016 IEEE International Interconnect Technology Conference / Advanced Metallization Conference (IITC/AMC). IEEE, 2016. http://dx.doi.org/10.1109/iitc-amc.2016.7507636.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Foulger, Alan. „Compressor Technology & High Pressure Air In Submarines“. In Warship 2002: Naval Submarines 7. RINA, 2002. http://dx.doi.org/10.3940/rina.ws.2002.18.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Wang, Ning C., Saurabh Sinha, Brian Cline, Chris D. English, Greg Yeric und Eric Pop. „Replacing copper interconnects with graphene at a 7-nm node“. In 2017 IEEE International Interconnect Technology Conference (IITC). IEEE, 2017. http://dx.doi.org/10.1109/iitc-amc.2017.7968949.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "AMQ 7"

1

DEFENSE ACQUISITION UNIV ALEXANDRIA VA. Acquisition Review Quarterly (ARQ) Vol 7, No. 2. Fort Belvoir, VA: Defense Technical Information Center, Januar 2000. http://dx.doi.org/10.21236/ada380592.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Trott, Christian Robert. Kokkos R&D: Remote Memory Spaces WBS STPR 04 Milestone 7. Office of Scientific and Technical Information (OSTI), September 2018. http://dx.doi.org/10.2172/1475257.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Moore, D. B. Demonstration of river crossing technology for installation of environmental horizontal wells: AMH-6 and AMH-7 installation report. Office of Scientific and Technical Information (OSTI), Juli 1993. http://dx.doi.org/10.2172/10191864.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Sasser, K. Risk assessment of CST-7 proposed waste treatment and storage facilities Volume I: Limited-scope probabilistic risk assessment (PRA) of proposed CST-7 waste treatment & storage facilities. Volume II: Preliminary hazards analysis of proposed CST-7 waste storage & treatment facilities. Office of Scientific and Technical Information (OSTI), Juni 1994. http://dx.doi.org/10.2172/10162854.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Arnold, Erik, Patries Boekholt, Barbara Good, Alfred Radauer, James Stroyan, Brigitte Tiefenthaler und Niki Vermeulen. Evaluation of Austrian Support Structures for FP 7 & Eureka and Impact Analysis of EU Research Initiatives on the Austrian Research & Innovation System. Technopolis Forschungs- und Beratungsges.m.b.H, November 2010. http://dx.doi.org/10.22163/fteval.2010.123.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

DUNCAN JB. REMOVAL OF TECHNETIUM 99 FROM THE EFFLUENT TREATMENT FACILITY (ETF) BASIN 44 USING PUROLITE A-530E & REILLEX HPQ & SYBRON IONAC SR-7 ION EXCHANGE RESINS. Office of Scientific and Technical Information (OSTI), Oktober 2004. http://dx.doi.org/10.2172/940010.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Kirkpatrick, Steven W., Robert T. Bocchieri, Fahim Sadek, Robert A. MacNeill, Samuel Holmes, Brian D. Peterson, Robert W. Cilke und Claudia Navarro. Analysis of aircraft impacts into the World Trade Center towers Chapters 1, 2, 3, 4, 5, 6, 7 & 8. Gaithersburg, MD: National Institute of Standards and Technology, 2005. http://dx.doi.org/10.6028/nist.ncstar.1-2bv1.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

M.G. JADICK. VERIFICATION SURVEY ACTIVITIES IN FS SURVEY UNITS 7, 8, 9, 10, 11, 13 & 14 AT THE SEPARATIONS PROCESS RESEARCH UNIT. Office of Scientific and Technical Information (OSTI), Mai 2010. http://dx.doi.org/10.2172/1003741.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

NAVAL OCEAN SYSTEMS CENTER SAN DIEGO CA. Proceedings of the Environmental Research and Development (R&D) technical Workshop Held in San Diego, California on 7-9 November 1989. Fort Belvoir, VA: Defense Technical Information Center, Juni 1990. http://dx.doi.org/10.21236/ada225806.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

ABB ENVIRONMENTAL SERVICES INC PORTLAND ME. Fort Devens Site Investigation for Groups 2, 7 & Historic Gas Stations. Revised Final Site Investigation Report. Data Item A009. Volume I. Report Text. Fort Belvoir, VA: Defense Technical Information Center, Oktober 1995. http://dx.doi.org/10.21236/ada328451.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!

Zur Bibliographie